Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Article Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostSubmitted by Chris Markoch. Originally Published: 2/5/2026. 
At a Glance - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average (DJIA) after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer delivered adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. Highlighting the report was Pfizer's announcement of positive topline results from the Phase 2b study of its lead GLP-1 candidate. In 2000, I told Barron's that a popular dot-com stock was headed for trouble. It dropped 90%. Now I'm making the opposite call on that same company: buy it now. This stock has become the lifeblood of AI data centers, yet almost no one has caught the story. While the media focuses on AI chip wars, they've missed this company's essential role in building out data centers. Their hardware is so critical that a single building uses enough of it to stretch around the world eight times. If you own Nvidia, you might want to pivot. If you missed Nvidia, this is your second chance at the AI data center buildout happening worldwide. See the under-the-radar play fueling AI data centers PFE stock closed up 4% on Feb. 4 as analysts and investors digested the report. The bullish case is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and its accelerating use of artificial intelligence across R&D. That story begins with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. Data show the global GLP-1 market growing from $62.2 billion in 2025 to $157 billion by 2035, a compound annual growth rate (CAGR) of about 9.7%. That growth helps explain why billions of dollars are flowing into companies trying to carve out market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study, which met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28 weeks. The Growth Driver Investors May Be Missing Immediately after the report, conventional wisdom focused on the positive clinical trial results as the reason for the stock gain. That may be true in the near term, but investors should be cautious about treating it as a lasting catalyst. While Pfizer's GLP-1 program shows promise, it will take time for those results to materially affect the company's financials. The GLP-1 trade is also expanding — and dominant players like Eli Lilly & Co. (NYSE: LLY) have signaled they intend to defend their obesity-drug leadership. There are, however, compelling reasons to be bullish on PFE beyond GLP-1s. One key area is oncology: Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026 and projects it will climb to $648.08 billion by 2035, a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had approximately 60 candidates in its product portfolio, translating to many opportunities to capture market share. The company's pipeline was significantly enhanced by its acquisition of Seagen in 2023. Today, Pfizer's portfolio includes late-stage candidates such as vepdegestrant, a next-generation targeted protein degrader (PROTAC) paired with atirmociclib, a selective CDK4 inhibitor, which are being evaluated for ER+/HER2- metastatic breast cancer. Other late-stage candidates include: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (for example, Be6A LUNG-01) targeting metastatic non-small cell lung cancer, leveraging Seagen's ADC expertise.
- Sasanlimab, being developed for bladder cancer, and a bispecific PD-1xVEGF agent (PF-4404) that is being combined with Padcev to treat urothelial cancer — all potential blockbusters amid oncology growth.
Pfizer could bring multiple drugs to market over the next five to ten years, and that prospect is amplified by the company's commitment to artificial intelligence (AI), which is becoming essential across the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships like Boltz for biomolecular modeling, XtalPi for molecular design, and Data4Cure for oncology data analytics. The company says tools such as OncoScout can speed target identification by at least 50%. Internally, platforms like "Charlie" are used for data mining, prediction, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) help optimize discovery and manufacturing. These efforts were important in Pfizer's rapid development of Paxlovid and support 2026 catalysts in oncology and obesity. The company is targeting $1.2 billion in savings by 2027 through efficiency gains. Industry-wide, AI is projected to boost productivity by roughly 35% to 45% by improving preclinical decision-making and trial design, making it a strategic advantage rather than mere hype. Pfizer has positioned itself early in AI adoption, which could provide meaningful benefits to investors over the medium and long term.
| 
